Guggenheim raised the firm’s price target on Humana (HUM) to $269 from $252 and keeps a Buy rating on the shares after the company reported Q1 EPS upside on favorable non-weather, non-flu related cost trend developments. Humana reported a solid quarter, “threading the needle against calls for potential miss/lower guide, and perhaps a misplaced position heading into 2027 bidding season,” the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana Kept at Hold as Analyst Raises Price Target to $267 Amid Margin-Rebuild Focus and Uncertain Medical Cost Trends
- Humana price target raised to $180 from $176 at Barclays
- Humana Charts Cautious Path in Earnings Call
- Why Is the SPY ETF Down Today, 4/29/2026?
- Morning Movers: NXP Semi, Bloom Energy charged up after results